user

Cardiovascular risk with concomitant use of stimulants and atypical antipsychotics in US children and adolescents

被引：0
|
作者：
Zhang, Chengchen [1 ]
Spence, O'Mareen [1 ]
Reeves, Gloria [2 ]
dosReis, Susan [1 ]
机构：
[1] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
5106
引用
收藏
页码：589 / 589
页数：1
相关论文
共 50 条
  • [31] Concomitant Use of Atypical Antipsychotics With Other Psychotropic Medication Classes and the Risk of Type 2 Diabetes Mellitus
    Burcu, Mehmet
    Zito, Julie M.
    Safer, Daniel J.
    Magder, Laurence S.
    dosReis, Susan
    Shaya, Fadia T.
    Rosenthal, Geoffrey L.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2017, 56 (08): : 642 - 651
  • [32] Combining stimulants with antipsychotics for foster children and adolescents: Do prescribers adhere to guidelines?
    Bush, Helena
    Rapp, John T.
    Kierce, Erica
    CHILDREN AND YOUTH SERVICES REVIEW, 2021, 121
  • [33] Atypical antipsychotics and their metabolic impact on psychiatrically hospitalized children and adolescents
    Silva, R. R.
    Ghaffari, M.
    Martinez, N.
    Teitel, E.
    Pappagallo, M.
    Gosselin, G.
    EUROPEAN PSYCHIATRY, 2008, 23 : S169 - S169
  • [34] Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents
    Toren, P
    Ratner, S
    Laor, N
    Weizman, A
    DRUG SAFETY, 2004, 27 (14) : 1135 - 1156
  • [35] Benefit-Risk Assessment of Atypical Antipsychotics in the Treatment of Schizophrenia and Comorbid Disorders in Children and Adolescents
    Paz Toren
    Sharon Ratner
    Nathaniel Laor
    Abraham Weizman
    Drug Safety, 2004, 27 : 1135 - 1156
  • [36] Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders
    Politte, Laura C.
    McDougle, Christopher J.
    PSYCHOPHARMACOLOGY, 2014, 231 (06) : 1023 - 1036
  • [37] Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders
    Laura C. Politte
    Christopher J. McDougle
    Psychopharmacology, 2014, 231 : 1023 - 1036
  • [38] RISK OF WEIGHT GAIN WITH THE USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI) AND ATYPICAL ANTIPSYCHOTICS (SGA) COMBINATION TREATMENT IN CHILDREN AND ADOLESCENTS
    Bhowmik, D.
    Chen, H.
    Aparasu, R. R.
    Bhatara, V
    VALUE IN HEALTH, 2010, 13 (03) : A180 - A181
  • [39] NATIONAL TRENDS IN OFF-LABEL USE OF ATYPICAL ANTIPSYCHOTICS IN CHILDREN AND ADOLESCENTS IN THE UNITED STATES
    Sohn, M.
    Moga, D. C.
    Blumenschein, K.
    Talbert, J.
    VALUE IN HEALTH, 2016, 19 (03) : A194 - A194
  • [40] National trends in off-label use of atypical antipsychotics in children and adolescents in the United States
    Sohn, Minji
    Moga, Daniela C.
    Blumenschein, Karen
    Talbert, Jeffery
    MEDICINE, 2016, 95 (23)
12345